Animal-Free Recombinant Human IGF-BP7
IGF-BPs controls the distribution, function and activity of IGFs in various cell tissues and body fluids. Currently there are seven named IGF-BPs that form high affinity complexes with both IGF-I and IGF-II. IGF-BP7 is expressed in a wide range of normal human tissues and it generally shows reduced expression in cancer cell lines of prostate, breast, colon, and lung origin. It plays a role in skeletal myogenesis by binding to IGF in a manner that inhibits IGF induced differentiation of skeletal myoblasts, without affecting IGF induced proliferation. Additionally, IGF-BP7 suppresses growth and colony formation of prostate and breast cancer cell lines through an IGF independent mechanism, which causes a delay in the G1 phase of the cell cycle, and increased apoptosis. Recombinant human IGF-BP7 is a 26.4 kDa protein consisting of 256 amino acid residues. Manufactured using all non-animal reagents.
Above 98% as determined by SDS-PAGE Analysis.
Testing In Progress.
SSSDTCGPC EPASCPPLP PLGCLLGET RDACGCCPM CARGEGEPC GGGGAGRGY CAPGMECVK SRKRRKGKA GAAAGGPGV SGVCVCKSR YPVCGSDGT TYPSGCQLR AASQRAESR GEKAITQVS KGTCEQGPS IVTPPKDIW NVTGAQVYL SCEVIGIPT PVLIWNKVK RGHYGVQRT ELLPGDRDN LAIQTRGGP EKHEVTGWV LVSPLSKED AGEYECHAS NSQGQASAS AKITVVDAL HEIPVKKGE GAEL
|Research Interest:||Apoptosis, Cancer, Proliferation and Cell Cycle, Metabolic Regulation and Diabetes|
|Protein Cross Reactivity:||NULL|